Skip to content
BioVie Inc. episode artwork

Aug 29, 2017 4 min

BioVie Inc.

from OTCQB Podcast Hosted by OTC Markets Group

100,000 patients in the U.S. have ascites due to advanced liver cirrhosis, with no approved drug to treat ascites. Jonathan Adams, CEO & CFO of BioVie Inc. (OTCQB: BIVI) discusses how the company is developing what they hope to be the first ever approved drug to treat ascites.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

BioVie Inc.

0:00 4:41

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OTCQB Podcast?

This episode is 4 minutes long.

When was this OTCQB Podcast episode published?

This episode was published on August 29, 2017.

Can I download this OTCQB Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.